Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.
2.

Editorial.

von Aulock S.

ALTEX. 2015;32(3):U2. No abstract available.

PMID:
26378294
3.

In vitro work.

von Aulock S.

ALTEX. 2015;32(2):U2. No abstract available.

PMID:
26042241
4.

30th anniversary of ALTEX.

von Aulock S.

ALTEX. 2014;31(4):U2. No abstract available.

PMID:
25538978
5.

Editorial.

von Aulock S.

ALTEX. 2014;31(3):U2. No abstract available.

PMID:
25184185
6.

Alternatives to animal experiments.

von Aulock S.

ALTEX. 2014;31(2):U2. No abstract available.

PMID:
24910879
7.

Number of animals used for experimental purposes lower in the European Union.

von Aulock S.

ALTEX. 2014;31(1):1. No abstract available.

PMID:
24600696
8.

Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.

Dietrich DR, von Aulock S, Marquardt H, Blaauboer B, Dekant W, Kehrer J, Hengstler J, Collier A, Gori GB, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A, Barile FA.

Toxicon. 2013 Dec 15;76:A1-A2. No abstract available.

PMID:
24409469
9.

Open letter to the European Commission: scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles.

Dietrich D, von Aulock S, Marquardt HW, Blaauboer BJ, Dekant W, Kehrer J, Hengstler JG, Collier AC, Gori GB, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A.

Arch Toxicol. 2013 Sep;87(9):1739-41. doi: 10.1007/s00204-013-1117-2. Epub 2013 Aug 27. No abstract available.

PMID:
23979651
10.

Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.

Dietrich DR, von Aulock S, Marquardt H, Blaauboer B, Dekant W, Kehrer J, Hengstler J, Collier A, Batta Gori G, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Wallace Hayes A, Gooderham N, Harvey A.

ALTEX. 2013;30(3):381-5. doi: 10.14573/altex.2013.3.381. No abstract available.

11.

Editorial.

Dietrich DR, von Aulock S, Marquardt H, Blaauboer B, Dekant W, Hengstler J, Collier A, Gori GB, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A.

Regul Toxicol Pharmacol. 2013 Dec;67(3):317-20. doi: 10.1016/j.yrtph.2013.07.001. Epub 2013 Jul 9. No abstract available.

PMID:
23850959
12.

Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.

Dietrich DR, von Aulock S, Marquardt H, Blaauboer B, Dekant W, Kehrer J, Hengstler J, Collier A, Gori GB, Pelkonen OP, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes A, Gooderham N, Harvey A.

Toxicol In Vitro. 2013 Oct;27(7):2110-4. doi: 10.1016/j.tiv.2013.07.001. Epub 2013 Jul 9. No abstract available.

PMID:
23850741
13.

Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.

Dietrich DR, von Aulock S, Marquardt H, Blaauboer B, Dekant W, Kehrer J, Hengstler J, Collier A, Gori GB, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A.

Food Chem Toxicol. 2013 Dec;62:A1-4. doi: 10.1016/j.fct.2013.07.005. Epub 2013 Jul 5. No abstract available.

PMID:
23835284
14.

Testing on animals. Editorial.

von Aulock S.

ALTEX. 2013;30(2):U2. No abstract available.

PMID:
23805430
15.

Evidence-Based Toxicology Collaboration (EBTC). Editorial.

von Aulock S.

ALTEX. 2013;30(1):1. No abstract available.

PMID:
23451363
16.

Alternative methods in Europe. Editorial.

von Aulock S.

ALTEX. 2012;29(3):249. No abstract available.

PMID:
23019682
17.

Apolipoprotein B100 is a suppressor of Staphylococcus aureus-induced innate immune responses in humans and mice.

Sigel S, Bunk S, Meergans T, Doninger B, Stich K, Stulnig T, Derfler K, Hoffmann J, Deininger S, von Aulock S, Knapp S.

Eur J Immunol. 2012 Nov;42(11):2983-9. doi: 10.1002/eji.201242564. Epub 2012 Aug 28.

18.

Guidance on determining indispensability and balancing potential benefits of animal experiments with costs to the animals with specific consideration of EU directive 2010/63/EU.

Lindl T, Gross U, Ruhdel I, von Aulock S, Völkel M.

ALTEX. 2012;29(2):219-28. doi: 10.14573/altex.2012.2.219. Erratum in: ALTEX. 2012;29(4):429-32. https://doi.org/10.14573/altex.2012.4.429.

19.

Developing alternatives to systemic toxicity testing approaches.

von Aulock S.

ALTEX. 2012;29(1):1. No abstract available.

PMID:
22408846
20.

Lipopolysaccharide pretreatment of the udder protects against experimental Escherichia coli mastitis.

Petzl W, Günther J, Pfister T, Sauter-Louis C, Goetze L, von Aulock S, Hafner-Marx A, Schuberth HJ, Seyfert HM, Zerbe H.

Innate Immun. 2012 Jun;18(3):467-77. doi: 10.1177/1753425911422407. Epub 2011 Oct 11.

PMID:
21990573
21.

Endogenous MCP-1 promotes lung inflammation induced by LPS and LTA.

van Zoelen MA, Verstege MI, Draing C, de Beer R, van't Veer C, Florquin S, Bresser P, van der Zee JS, te Velde AA, von Aulock S, van der Poll T.

Mol Immunol. 2011 Jul;48(12-13):1468-76. doi: 10.1016/j.molimm.2011.04.001. Epub 2011 May 6.

PMID:
21529952
22.

Validation is a key theme in this issue of ALTEX.

von Aulock S.

ALTEX. 2011;28(1):1. No abstract available.

PMID:
21404727
23.

Internalization and coreceptor expression are critical for TLR2-mediated recognition of lipoteichoic acid in human peripheral blood.

Bunk S, Sigel S, Metzdorf D, Sharif O, Triantafilou K, Triantafilou M, Hartung T, Knapp S, von Aulock S.

J Immunol. 2010 Sep 15;185(6):3708-17. doi: 10.4049/jimmunol.0901660. Epub 2010 Aug 16.

24.

The patchwork of toxicological research for pharmaceutical testing.

von Aulock S.

ALTEX. 2010;27(1):1. No abstract available.

PMID:
20397314
25.

2-APB and capsazepine-induced Ca2+ influx stimulates clathrin-dependent endocytosis in alveolar epithelial cells.

Usmani SM, Fois G, Albrecht S, von Aulock S, Dietl P, Wittekindt OH.

Cell Physiol Biochem. 2010;25(1):91-102. doi: 10.1159/000272064. Epub 2009 Dec 22.

26.

Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury.

Lai Y, Di Nardo A, Nakatsuji T, Leichtle A, Yang Y, Cogen AL, Wu ZR, Hooper LV, Schmidt RR, von Aulock S, Radek KA, Huang CM, Ryan AF, Gallo RL.

Nat Med. 2009 Dec;15(12):1377-82. doi: 10.1038/nm.2062. Epub 2009 Nov 22.

27.

Assessment of pyrogenic contaminations with validated human whole-blood assay.

Daneshian M, von Aulock S, Hartung T.

Nat Protoc. 2009;4(12):1709-21. doi: 10.1038/nprot.2009.159. Epub 2009 Nov 5.

PMID:
19893507
28.

IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex.

Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, Synguelakis M, von Aulock S, Sallenave JM, McKenzie AN, Kanellopoulos J.

J Immunol. 2009 Jul 15;183(2):1446-55. doi: 10.4049/jimmunol.0803067. Epub 2009 Jun 24.

29.
30.

Activation of coagulation and inhibition of fibrinolysis in the human lung on bronchial instillation of lipoteichoic acid and lipopolysaccharide.

Hoogerwerf JJ, de Vos AF, Levi M, Bresser P, van der Zee JS, Draing C, von Aulock S, van der Poll T.

Crit Care Med. 2009 Feb;37(2):619-25. doi: 10.1097/CCM.0b013e31819584f9.

PMID:
19114879
31.

IL-10 release requires stronger toll-like receptor 4-triggering than TNF: a possible explanation for the selective effects of heterozygous TLR4 polymorphism Asp(299)Gly on IL-10 release.

Dehus O, Bunk S, von Aulock S, Hermann C.

Immunobiology. 2008;213(8):621-7. doi: 10.1016/j.imbio.2008.03.001. Epub 2008 May 23.

PMID:
18950592
32.

Presentation of lipoteichoic acid potentiates its inflammatory activity.

Deininger S, Traub S, Aichele D, Rupp T, Baris T, Möller HM, Hartung T, von Aulock S.

Immunobiology. 2008;213(6):519-29. doi: 10.1016/j.imbio.2008.01.001. Epub 2008 Feb 14.

PMID:
18514754
33.

D-alanylation of lipoteichoic acid contributes to the virulence of Streptococcus suis.

Fittipaldi N, Sekizaki T, Takamatsu D, Harel J, Domínguez-Punaro Mde L, Von Aulock S, Draing C, Marois C, Kobisch M, Gottschalk M.

Infect Immun. 2008 Aug;76(8):3587-94. doi: 10.1128/IAI.01568-07. Epub 2008 May 12. Erratum in: Infect Immun. 2008 Dec;76(12):5892-3. Infect Immun. 2009 May;77(5):2240.

34.

High sensitivity pyrogen testing in water and dialysis solutions.

Daneshian M, Wendel A, Hartung T, von Aulock S.

J Immunol Methods. 2008 Jul 20;336(1):64-70. doi: 10.1016/j.jim.2008.03.013. Epub 2008 Apr 24.

PMID:
18474369
35.

Cellular trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signaling: role of CD14 and CD36.

Nilsen NJ, Deininger S, Nonstad U, Skjeldal F, Husebye H, Rodionov D, von Aulock S, Hartung T, Lien E, Bakke O, Espevik T.

J Leukoc Biol. 2008 Jul;84(1):280-91. doi: 10.1189/jlb.0907656. Epub 2008 May 5.

36.

Endogenous beta-adrenergic receptors inhibit lipopolysaccharide-induced pulmonary cytokine release and coagulation.

Giebelen IA, Leendertse M, Dessing MC, Meijers JC, Levi M, Draing C, von Aulock S, van der Poll T.

Am J Respir Cell Mol Biol. 2008 Sep;39(3):373-9. doi: 10.1165/rcmb.2007-0439OC. Epub 2008 Apr 17.

PMID:
18421015
37.

Cytokine induction by Gram-positive bacteria.

Draing C, Sigel S, Deininger S, Traub S, Munke R, Mayer C, Hareng L, Hartung T, von Aulock S, Hermann C.

Immunobiology. 2008;213(3-4):285-96. doi: 10.1016/j.imbio.2007.12.001. Epub 2008 Feb 19. Review.

PMID:
18406374
38.

Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans.

Hoogerwerf JJ, de Vos AF, Bresser P, van der Zee JS, Pater JM, de Boer A, Tanck M, Lundell DL, Her-Jenh C, Draing C, von Aulock S, van der Poll T.

Am J Respir Crit Care Med. 2008 Jul 1;178(1):34-41. doi: 10.1164/rccm.200708-1261OC. Epub 2008 Apr 10.

PMID:
18403723
39.

Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor.

Knapp S, von Aulock S, Leendertse M, Haslinger I, Draing C, Golenbock DT, van der Poll T.

J Immunol. 2008 Mar 1;180(5):3478-84.

40.

Polypropylene glycol is a selective binding inhibitor for LTA and other structurally related TLR2 agonists.

Draing C, Traub S, Deininger S, Mang P, Möller HM, Manso M, Rossi F, Morath S, Hartung T, von Aulock S.

Eur J Immunol. 2008 Mar;38(3):797-808. doi: 10.1002/eji.200737466.

41.

Role played by Toll-like receptors 2 and 4 in lipoteichoic acid-induced lung inflammation and coagulation.

Dessing MC, Schouten M, Draing C, Levi M, von Aulock S, van der Poll T.

J Infect Dis. 2008 Jan 15;197(2):245-52. doi: 10.1086/524873.

PMID:
18179383
42.
43.

Use of synthetic derivatives to determine the minimal active structure of cytokine-inducing lipoteichoic acid.

Deininger S, Figueroa-Perez I, Sigel S, Stadelmaier A, Schmidt RR, Hartung T, von Aulock S.

Clin Vaccine Immunol. 2007 Dec;14(12):1629-33. Epub 2007 Oct 10.

44.

Intrapulmonary delivery of ethyl pyruvate attenuates lipopolysaccharide- and lipoteichoic acid-induced lung inflammation in vivo.

van Zoelen MA, de Vos AF, Larosa GJ, Draing C, von Aulock S, van der Poll T.

Shock. 2007 Nov;28(5):570-5.

PMID:
17577142
45.

Functional analysis of D-alanylation of lipoteichoic acid in the probiotic strain Lactobacillus rhamnosus GG.

Perea Vélez M, Verhoeven TL, Draing C, Von Aulock S, Pfitzenmaier M, Geyer A, Lambrichts I, Grangette C, Pot B, Vanderleyden J, De Keersmaecker SC.

Appl Environ Microbiol. 2007 Jun;73(11):3595-604. Epub 2007 Apr 13.

46.

Molecular interaction between lipoteichoic acids and Lactobacillus delbrueckii phages depends on D-alanyl and alpha-glucose substitution of poly(glycerophosphate) backbones.

Räisänen L, Draing C, Pfitzenmaier M, Schubert K, Jaakonsaari T, von Aulock S, Hartung T, Alatossava T.

J Bacteriol. 2007 Jun;189(11):4135-40. Epub 2007 Apr 6.

47.

Comment on "Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus".

von Aulock S, Hartung T, Hermann C.

J Immunol. 2007 Mar 1;178(5):2610; author reply 2610-1. No abstract available.

48.

An in vitro pyrogen safety test for immune-stimulating components on surfaces.

Hasiwa M, Kullmann K, von Aulock S, Klein C, Hartung T.

Biomaterials. 2007 Mar;28(7):1367-75. Epub 2006 Dec 8.

PMID:
17157907
49.

In vitro pyrogen test--A new test method for solid medical devices.

Mazzotti F, Beuttler J, Zeller R, Fink U, Schindler S, Wendel A, Hartung T, von Aulock S.

J Biomed Mater Res A. 2007 Feb;80(2):276-82.

PMID:
16958052
50.

Comparison of lipoteichoic acid from different serotypes of Streptococcus pneumoniae.

Draing C, Pfitzenmaier M, Zummo S, Mancuso G, Geyer A, Hartung T, von Aulock S.

J Biol Chem. 2006 Nov 10;281(45):33849-59. Epub 2006 Aug 29.

Supplemental Content

Loading ...
Support Center